Bicara Therapeutics (NASDAQ:BCAX) Price Target Cut to $36.00 by Analysts at HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its price target cut by HC Wainwright from $42.00 to $36.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also issued reports on BCAX. Benchmark restated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, October 29th. BTIG Research dropped their price objective on Bicara Therapeutics from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Tuesday. Wells Fargo & Company increased their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a report on Wednesday, August 12th. BMO Capital Markets began coverage on Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, The Goldman Sachs Group lowered Bicara Therapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $20.00 to $8.00 in a research note on Friday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.

Bicara Therapeutics Stock Performance

BCAX opened at $10.53 on Wednesday. Bicara Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $30.99. The firm has a 50-day moving average of $17.37 and a 200 day moving average of $20.84. The firm has a market cap of $696.80 million, a P/E ratio of -3.03 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.22). Equities research analysts predict that Bicara Therapeutics will post -3.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in shares of Bicara Therapeutics by 33.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company’s stock valued at $827,000 after purchasing an additional 11,086 shares during the period. Nan Fung Trinity HK Ltd. lifted its holdings in Bicara Therapeutics by 49.9% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company’s stock worth $7,963,000 after purchasing an additional 142,390 shares in the last quarter. Alps Advisors Inc. lifted its holdings in Bicara Therapeutics by 32.5% during the 3rd quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock worth $1,632,000 after purchasing an additional 21,510 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the 3rd quarter worth about $63,000. Finally, Profund Advisors LLC boosted its stake in Bicara Therapeutics by 7.2% in the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after purchasing an additional 1,140 shares during the period.

Key Bicara Therapeutics News

Investors following BCAX have been watching these news items:

• Positive Sentiment: Bicara’s Q3 2026 earnings-call coverage highlighted strong enrollment momentum, a potentially encouraging sign for progress in its clinical programs. Article: Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights
• Neutral Sentiment: A report listed short interest at zero shares as of Nov. 10. That figure indicates no reported short position in the data, but provides little evidence of short-covering demand.
• Negative Sentiment: All four firms lowered their price targets: HC Wainwright to $36 from $42; Morgan Stanley to $30 from $41; Stifel to $43 from $45; and BTIG to $37 from $39. The cuts point to more cautious assumptions even though the firms maintained bullish ratings. Separately, Bicara reported a Q3 loss of $1.04 per share, wider than the $0.82 loss analysts expected.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.